Gemer Ofer, Uriev Leonid, Harkovsky Tatiana, Peled Ronit, Ben-Dor David, Barak Frida, Segal Shmuel
Department of Obstetrics and Gynecology, Pathology Institute, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Ashkelon, Israel
J Reprod Med. 2004 Sep;49(9):703-6.
To determine whether lower uterine segment involvement (LUSI) correlates with recurrence and survival in women with stage I endometrial adenocarcinoma who do not receive postoperative radiotherapy on the basis of this histologic criterion.
Eighty patients with endometrial adenocarcinoma stage I who underwent surgery between 1989 and 2002 were divided into 2 groups according to the presence of LUSI. Group 1 consisted of 25 patients with LUSI; group 2 consisted of 55 patients without LUSI. The 2 groups were compared with regard to prognostic factors and outcome measures.
There were no statistically significant differences between the 2 groups with regard to the following parameters: age and proportion of patients who underwent complete surgical staging and postoperative adjuvant radiotherapy. Pathologic parameters of the 2 groups, such as histologic type, grade and deep myometrial invasion, were comparable. A greater proportion of patients with LUSI had capillary space-like involvement. The patients were followed for a median of 48 months (range, 11-168) from the date of surgery. The overall 5-year recurrence-free survival, disease-specific survival and overall survival rates were 91% (SE .04), 94% (SE .03) and 77% (SE .06), respectively. There was no significant difference between the two groups with regards to these measures (P < .05).
In patients with state I endometrial cancer, the presence of lower uterine segment involvement does not correlate with their outcome.
基于这一组织学标准,确定子宫下段受累(LUSI)是否与未接受术后放疗的I期子宫内膜腺癌女性的复发及生存情况相关。
1989年至2002年间接受手术的80例I期子宫内膜腺癌患者根据是否存在子宫下段受累分为两组。第1组由25例子宫下段受累患者组成;第2组由55例无子宫下段受累患者组成。比较两组的预后因素和结局指标。
两组在以下参数方面无统计学显著差异:年龄、接受完整手术分期和术后辅助放疗的患者比例。两组的病理参数,如组织学类型、分级和肌层深部浸润情况具有可比性。子宫下段受累患者中毛细血管间隙样受累的比例更高。自手术之日起,患者的中位随访时间为48个月(范围11 - 168个月)。总体5年无复发生存率、疾病特异性生存率和总生存率分别为91%(标准误0.04)、94%(标准误0.03)和77%(标准误0.06)。两组在这些指标方面无显著差异(P < 0.05)。
在I期子宫内膜癌患者中,子宫下段受累与患者的结局无关。